Power of K-combos...Rosuzet leads outpatient Rx drug market
By Chon, Seung-Hyun | translator Kim, Jung-Ju
23.07.19 06:20:08
가나다라
0
Q2 outpatient prescriptions...Rosuzet overtakes the lead for the first time in Korea
Rosuzet’s prescriptions in 1H amount to KRW 85.3 billion...reserves a seat in the KRW 100 billion sales club for 4 consecutive years
Homegrown new drug K-cab’s sales in Q2 record KRW 38.5 billion... continues on its high march
Hanmi Pharmaceutical’s new combination drug Rosuzet is ruling the outpatient prescription market in Korea. Rosuzet became the first domestically developed drug to lead quarterly outpatient prescriptions sales. Sales of HK Inno.N’s new drug ‘K-cab’ also continued to grow, taking part in the lead owned by domestically developed drugs in the outpatient prescription market.
According to the market research institution UBIST, Hanmi Pharmaceutical’s Rosuzet recorded the most in outpatient prescriptions in Q2 with KRW 43.8 billion. Its sales rose 19.5% YoY and overtook the lead in quarterly prescriptions for the first time. Viatris’s Lipitor, which had held the lead until Q1 last year, was overtaken for the
Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)